With specialty drug spend on the rise and a robust pipeline of specialty drugs, specialty drug management remains a top concern for payers. The 2024 State of Specialty Spend and Trend Report uses integrated pharmacy and medical claims data to provide a comprehensive overview of specialty drug spend and trend. It offers the most in-depth analysis available on specialty drug spend, utilizing PSG’s Artemetrx platform to present real-world data on the current state of specialty spend and trend, including management strategies.
Key Takeaways
Here’s a sneak peak into a few of the key findings:
- Despite downward pressure by biosimilars and generic specialty drugs, specialty drug spend and trend increased in 2023
- Claim utilization and cost per claim both contribute substantially to specialty drug trend
- The percentage of members who use specialty drugs continues to rise, with no signs of leveling off
- Humira remains the top specialty drug by spend, but Skyrizi rose from #6 in 2022 to #3 in 2023
- Biosimilars are continuing to gain traction in the U.S. market, with especially large increases in market share of the biosimilars for Lucentis and Remicade
